Antibodies to HLA-E may account for the non-donor-specific anti-HLA class-Ia antibodies in renal and liver transplant recipients

International Immunology

Volumn 24, Issue 1, 2012, Pages 43-57

  Ravindranath, Mepur H ^a   Pham, Tho ^a   Ozawa, Miyuki ^a   Terasaki, Paul I ^a  

^a TERASAKI FOUNDATION LABORATORY   (United States)

Author keywords

HLA E; HLA Ia; Kidney transplantation; Liver transplantation

Indexed keywords

HLA ANTIBODY; HLA E ANTIGEN; IMMUNOGLOBULIN G; PROTEIN G;

ALLELE; ALLOGRAFT; AMINO ACID SEQUENCE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEAVY CHAIN; HUMAN; IMMUNOREACTIVITY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SURVIVAL;

EID: 84855414378     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxr094     Document Type: Article

References (35)

1. Bjorkman, P. J. and Parham, P. 1990. Structure, function, and diversity of class I major histocompatibility complex molecules. Ann. Rev. Biochem. 59:253.
2. Rodgers, J. R. and Cook, R. G. 2005. MHC class Ib molecules bridge innate and acquired immunity. Nature Rev. Immunol. 5:459.
3. Raine, T., Brown, D., Bowness, P. et al. 2006. Consistent patterns of expression of HLA class I free heavy chains in healthy individuals and raised expression in spondyloarthropathy patients point to physiological and pathological roles. Rheumatol. (Oxford) 45:1338.
4. Ulbrecht, M., Couturier, A., Martinozzi, S. et al. 1999. Cell surface expression of HLA-E: interaction with human β2-microglobulin and allelic differences. Eur. J. Immunol. 29:537.
5. Strong, R. K., Holmes, M. A., Li, P., Braun, L., Lee, N. and Geraghty, D. E. 2003. HLA-E allelic variants: correlating differential expression, peptide affinities, crystal structures and thermal stabilities. J. Biol. Chem. 278:5082.
6. Grimsley, C., Kawasaki, A., Gassner, C. et al. 2002. Definitive high resolution typing of HLA-E allelic polymorphisms: identifying potential errors in existing allele data. Tissue Antigens 60:206.
7. Coupel, S., Moreau, A., Hamidou, M., Horejsi, V., Soulillou, J. P. and Charreau, B. 2007. Expression and release of sHLA-E is an immunoregulatory feature of EC activation. Blood 109:2806.
8. Wei, X. and Orr, H. T. 1990. Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue. Human Immunol. 29:131.
9. Derré, L., Corvaisier, M., Charreau, B. et al. 2006. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J. Immunol. 177:3100.
10. Marin, R., Ruiz-Cabello, F., Pedrinaci, S. et al. 2003. Analysis of HLA-E expression in human tumors. Immunogenetics 54:767.
11. Algarra, I., García-Lora, A., Cabrera, T., Ruiz-Cabello, F and Garrido, F. 2004. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol. Immunother. 53:904.
12. + cells. J. Neuroimmunol. 189:50.
13. Levy, E. M., Bianchini, M., Von Euw, E. M. et al. 2008. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int. J. Oncol. 32:633.
14. Berezhnoǐ, A. E., Chernisheva, A. D., Zakeeva, I. R. et al. 2009. HLA-E molecule induction on the surface of tumor cells protects them from cytotoxic lymphocytes. Vopr. Onkol. 55:224.
15. Hanak, L., Slaby, O., Lauerova, L., Kren, L., Nenutil, R. and Michalek, J. 2009. Expression pattern of HLA class I antigens in renal cell carcinoma and primary cell line cultures: methodological implications for immunotherapy. Med. Sci. Monit. 15:638.
16. de Kruijf, E. M., Sajet, A., van Nes, J. G. et al. 2010. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J. Immunol. 185:7452.
17. Kren, L., Slaby, O., Muckova, K. et al. 2011. Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: an unexpected prognostic significance? Neuropathol. 31:129.
18. Gooden, M., Lampen, M., Jordanova, E. S. et al. 2011. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes. Proc. Natl Acad. Sci. USA 108:10656.
19. Allard, M., Oger, R., Vignard, V. et al. 2011. Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer. PLoS One 6:e21118.
20. Prigione, I., Penco, F., Martini, A., Gattorno, M., Pistoia, V. and Morandi, F. 2011. HLA-G and HLA-E in patients with juvenile idiopathic arthritis. Rhematol. 50:966.
21. Riederer, I., Sievert, W., Eissner, G., Molls, M. and Multhoff, G. 2010. Irradiation-induced up-regulation of HLA-E on macrovascular EC confers protection against killing by activated NK Cells. PLoS one 5:e15339.
22. Ravindranath, M. H., Taniguchi, M. C., Chen, W. et al. 2010. HLA-E monoclonal Abs recognize shared peptide sequences on classical HLA class Ia: relevance to human natural HLA antibodies. Mol. Immunol. 47:1121.
23. Ravindranath, M. H., Kaneku, H. and El-Awar, N. 2010. HLA-E monoclonal Ab MEM-E/02 binds to discontinuous but shared peptide sequences on HLA B & C heavy chains not treated by acid. Mol. Immunol. 47:1663.
24. Ravindranath, M. H., Pham, T., El-Awar, N., Kaneku, H. and Terasaki, P. I. 2011. Anti-HLA-E monoclonal Ab 3D12 mimics MEM-E/02 in binding to HLA-B and HLA-C alleles: web-tools validate the Immunogenic epitopes of HLA-E recognized by the antibodies. Mol. Immunol. 48:423.
25. Ravindranath, M. H., Kaneku, H., El-Awar, N., Morales-Buenrostro, L. E. and Terasaki, P. I. 2010. Antibodies to HLA-E in nonalloimmunized males: pattern of HLA-Ia-reactivity of Anti-HLA-E-positive sera. J. Immunol. 185:1935.
26. Lachmann, N., Terasaki, P. I., Budde, K. et al. 2009. Anti-human leukocyte antigen and donor-specific Abs. detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 87:1505.
27. Goh, A., Scalamogna, M., De Feo, T., Poli, F. and Terasaki, P. I. 2010. Human leukocyte antigen crossmatch testing is important for liver retransplantation. Liver Transpl. 16:308.
28. Hourmant, M., Cesbron-Gautier, A., Terasaki, P. I. et al. 2005. Frequency and clinical implications of development of donor specific and non-donor specific HLA antibodies after kidneytransplantation. J. Am. Soc. Nephrol. 16:2804.
29. El-Awar, N., Lee, J. H., Tarsitani, C. and Terasaki, P. I. 2007. HLA class I epitopes: recognition of binding sites by mAbs or eluted alloantibody confirmed with single recombinant antigens. Human Immunol. 68:170.
30. El-Awar, N., Akaza, T., Terasaki, P. I. and Nguyen, A. 2007. Human leukocyte antigen class I epitopes: update to 103 total epitopes, including the C locus. Transplantation 84:532.
31. El-Awar, N., Terasaki, P. I., Cai, J. et al. 2009. Epitopes of HLA-A, B, C, DR, DQ, DP and MICA antigens. Clin. Transpl. 2009:295.
32. Puppo, F., Bignardi, D., Contini, P. et al. 1999. β2m-free HLA class I HC levels in sera of healthy individuals. Lack of association with β2m-associated HLA class I heavy chain levels and HLA phenotype. Tissue Antigens 53:253.
33. Pickl, W. F., Majdic, O., Faé, I., Reuschel, R., Holter, W. and Knapp, W. 1993. The soluble pool of b2m free HLA class I alphachains. Qualitative and quantitative characterization. J. Immunol. 151:2613.
34. DeVito-Haynes, L. D., Demaria, S., Bushkin, Y. and Burlingham, W. J. 1998. The metalloproteinase-mediated pathway is essential for generation of soluble HLA class I proteins by activated cells in vitro: proposed mechanism for soluble HLA release in transplant rejection. Hum. Immunol. 59:426.
35. Ametani, A., Apple, R., Bhardwaj, V., Gammon, G., Miller, A. and Sercarz, E. 1989. Examining the crypticity of antigenic determinants. Cold Spring Harb. Symp. Quant. Biol. 54:505.